Biomedical Engineering Reference
In-Depth Information
in order to improve the oral bioavailability of the drug because the proportion of
M-cells in the intestinal epithelia is very low. However, it does not avoid toxicity
cancer drug concerns because free distribution of the drug to organs other than
tumour after blood systemic circulation arrival.
Other modality of cancer treatment, the cancer immunotherapy, could also profit
the targeting of M-cells with particles. However, it must face up the natural tendency
of oral mucosa to induce tolerance besides the immunosupressive mechanisms of
tumour itself. This fact adds an unjustifiable factor of complexity in the design of
effective cancer vaccines that need to be rethought.
It will be necessary more and deeper studies with in vivo imaging techniques to
clarify the correlation between nanoparticle properties and their interaction with the
GI mucosa, their transport through and their final outcome. In this context, the
strategies used by microorganisms capable to cross the intestinal epithelia and
invade other organs should be extrapolated to nanocarriers design.
References
Agoram B, Woltosz WS, Bolger MB (2001) Predicting the impact of physiological and biochemi-
cal processes on oral drug bioavailability. Adv Drug Deliv Rev 50 Suppl 1:S41-67.
doi:S0169409X0100179X [pii]
Agueros M, Ruiz-Gaton L, Vauthier C, Bouchemal K, Espuelas S, Ponchel G, Irache JM (2009)
Combined hydroxypropyl-beta-cyclodextrin and poly(anhydride) nanoparticles improve the
oral permeability of paclitaxel. Eur J Pharm Sci 38 (4):405- 413. doi:S0928-0987(09)00269-3
[pii] 10.1016/j.ejps.2009.09.010
Agueros M, Zabaleta V, Espuelas S, Campanero MA, Irache JM (2010) Increased oral bioavail-
ability of paclitaxel by its encapsulation through complex formation with cyclodextrins in
poly(anhydride) nanoparticles. J Control Release 145 (1):2-8. doi:S0168-3659(10)00217-8
[pii] 10.1016/j.jconrel.2010.03.012
Albert A (1958) Chemical aspects of selective toxicity. Nature 182 (4633):421-422
Almeida AJ, Souto E (2007) Solid lipid nanoparticles as a drug delivery system for peptides and
proteins. Adv Drug Deliv Rev 59 (6):478-490. doi:S0169-409X(07)00043-9 [pii] 10.1016/j.
addr.2007.04.007
Arbos P, Arangoa MA, Campanero MA, Irache JM (2002) Quantification of the bioadhesive
properties of protein-coated PVM/MA nanoparticles. Int J Pharm 242 (1-2):129-136.
doi:S0378517302001825 [pii]
Arbos P, Campanero MA, Arangoa MA, Renedo MJ, Irache JM (2003) Influence of the surface
characteristics of PVM/MA nanoparticles on their bioadhesive properties. J Control Release
89 (1):19-30. doi:S016836590300066X [pii]
Arbos P, Campanero MA, Arangoa MA, Irache JM (2004) Nanoparticles with specific bioadhe-
sive properties to circumvent the pre-systemic degradation of fluorinated pyrimidines.
J Control Release 96 (1):55-65. doi:10.1016/j.jconrel.2004.01.006 S0168365904000288 [pii]
Arima H, Yunomae K, Hirayama F, Uekama K (2001) Contribution of P-glycoprotein to the
enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus.
J Pharmacol Exp Ther 297 (2):547-555
Armstrong RD, Diasio RB (1980) Metabolism and biological activity of 5ยข-deoxy-5-fluorouridine,
a novel fluoropyrimidine. Cancer Res 40 (9):3333-3338
Artursson P, Palm K, Luthman K (2001) Caco-2 monolayers in experimental and theoretical predic-
tions of drug transport. Adv Drug Deliv Rev 46 (1-3):27-43. doi:S0169-409X(00)00128-9 [pii]
Search WWH ::
Custom Search